Ericksonian hypnosis in chronic care support groups.
Nurs Sci Q. 2007 Oct;20(4):357-69. Larkin DM. The College of New Rochelle, School of Nursing, New Rochelle, New York, USA.
Welcome to The International Hypnosis Research Institute Web site. Our intention is to provide quality information to clinicians and the general public concerning hypnosis, hypnotherapy, and other mind/body modalities. We intend to expand our coverage to include such topics as Neuro-Linguistic Programming (NLP), energy psychology and medicine, and other related topics. While our intention is to provide quality information derived from valid sources, including peer reviewed literature concerning significant research, this site is not presented as a source of medical or psychological advice. Clinicians wishing to expand their scope of practice or protocols based upon presented information should perform due diligence prior to use. It is our sincere hope to stimulate interest in these topics and to contribute to the evolution of the science of hypnosis. -- Tim Brunson DCH
Nurs Sci Q. 2007 Oct;20(4):357-69. Larkin DM. The College of New Rochelle, School of Nursing, New Rochelle, New York, USA.
by Anne Spencer, Ph.D.
One of the most unexpected events in my life was to be doing a regression for weight reduction and find myself involved in an exorcism.
It happened this way. I was asked to work with a national author and speaker who had a weight problem. We'll call her Rose. I first met rose via telephone as I had written her to say how much her book had helped me understand myself and some of my clients. Rose called to thank me and said she would be in my city a few months hence. We met for lunch and the friendship began.
Am J Clin Hypn. 2007 Oct;50(2):121-9. Berberich FR. Pediatric Medical Group, Berkeley, CA 94705, USA. rberb@sbcglobal.net
Br J Psychol. 2007 Nov;98(Pt 4):547-74. Subbotsky E. Psychology Department, Lancaster University, Lancaster, UK. e.subbotsky@lancaster.ac.uk
Int J Neuropsychopharmacol. 2007 Nov 30;:1-5 Lichtenberg P, Even-Or E, Bar G, Levin R, Brin A, Heresco-Levy U. Hadassah Medical School of the Hebrew University of Jerusalem, Israel.
Neurosci Behav Physiol. 2008 Jan;38(1):23-30. Galashina AG, Kulikov MA, Bogdanov AV. Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, bogdav@mail.ru.
Hong Kong Med J. 2008 Apr;14(2):110-5. Xue CC, Zhang AL, Holroyd E, Suen LK. Division of Chinese Medicine, School of Health Sciences, The WHO Collaborating Centre for Traditional Medicine, RMIT University, Melbourne, Australia.
Am J Clin Hypn. 2008 Jan;50(3):233-45. Amundson JK, Nuttgens SA. Amundson & Associates, 1614 8th Avenue NW, Calgary. aapsych@telus.net
Am J Clin Hypn. 2008 Jan;50(3):247-57. Roffman AE. New York University, Child Study Center, 577 First Avenue, New York, NY 10016, USA. roffma01@med.nyu.edu
Contact Dermatitis. 2008 Feb;58(2):97-100. de Medeiros LM, Fransway AF, Taylor JS, Wyman M, Janes J, Fowler JF Jr, Rietschel RL. Section of Industrial Dermatology, Department of Dermatology (A-61), Cleveland Clinic, Cleveland, OH 44195, USA.
J Pediatr Psychol. 2008 Mar;33(2):195-207. Epub 2007 Sep 10. Nassau JH, Tien K, Fritz GK. Bradley Hasbro Children's Research Center, CORO Center West - Suite 204, 1 Hoppin Street, Providence, RI 02903, USA. jack_nassau@brown.edu
Int J Clin Exp Hypn. 2008 Apr;56(2):119-42. Wagstaff GF, Cole JC, Brunas-Wagstaff J. University of Liverpool, Liverpool, UK.
Am J Clin Hypn. 2007 Apr;49(4):283-7. Page RA, Green JP. Ohio State University, 4240 Campus Drive, Lima, Ohio 45804, USA. page.6@osu.edu
Curr Allergy Asthma Rep. 2007 May;7(2):100-4. Eccles R. Common Cold Centre, Cardiff School of Biosciences, Cardiff University, Cardiff CF10 3US, UK. eccles@cardiff.ac.uk
Psychol Sci. 2007 Jun;18(6):503-9. Ceci SJ, Papierno PB, Kulkofsky S. Department of Human Development, Cornell University, NY 14853, USA. sjc9@cornell.edu
Am J Clin Hypn. 2007 Jul;50(1):29-36. Hypnobo: perspectives on hypnosis and placebo.Raz A. Vancouver Coastal Health Research Institute.
However, if a multiple of the 7 factors are positive as in the included case report, referral to an appropriate psychotherapist is recommended.
Am J Clin Hypn. 2007 Oct;50(2):131-6. Shenefelt PD. Department of Dermatology and Cutaneous Surgery, University of South Florida, Tampa, Florida 33612, USA. pshenefe@health.usf.edu
Am J Clin Hypn. 2007 Oct;50(2):157-70. Torem MS. North East Ohio Universities College of Medicine, USA. mtorem@agmc.org
Am J Clin Hypn. 2007 Apr;49(4):267-81. Rossi EL, Rossi KL. Ernest@ErnestRossi.com
Objective: To examine the contribution of 2 different neurotransmitters, the endogenous opioid and the dopaminergic (DA) systems, to the development of placebo and nocebo effects.
Design and Setting: Using a within-subject design, subjects twice underwent a 20-minute standardized pain challenge, in the absence and presence of a placebo with expected analgesic properties. Studies were conducted in a university hospital setting.
Participants: Twenty healthy men and women aged 20 to 30 years recruited by advertisement.
Main Outcome Measures: Activation of DA and opioid neurotransmission by a pain stressor with and without placebo (changes in the binding potential of carbon 11 [11C]?labeled raclopride and [11C] carfentanil with positron emission tomography) and ratings of pain, affective state, and anticipation and perception of analgesia.
Results: Placebo-induced activation of opioid neurotransmission was detected in the anterior cingulate, orbitofrontal and insular cortices, nucleus accumbens, amygdala, and periaqueductal gray matter. Dopaminergic activation was observed in the ventral basal ganglia, including the nucleus accumbens. Regional DA and opioid activity were associated with the anticipated and subjectively perceived effectiveness of the placebo and reductions in continuous pain ratings. High placebo responses were associated with greater DA and opioid activity in the nucleus accumbens. Nocebo responses were associated with a deactivation of DA and opioid release. Nucleus accumbens DA release accounted for 25% of the variance in placebo analgesic effects.
Conclusions: Placebo and nocebo effects are associated with opposite responses of DA and endogenous opioid neurotransmission in a distributed network of regions. The brain areas involved in these phenomena form part of the circuit typically implicated in reward responses and motivated behavior.
David J. Scott, BS; Christian S. Stohler, DDS, PhD; Christine M. Egnatuk, BS; Heng Wang, PhD; Robert A. Koeppe, PhD; Jon-Kar Zubieta, MD, PhD Author Affiliations: Department of Psychiatry and Molecular and Behavioral Neuroscience Institute (Mr Scott, Ms Egnatuk, and Drs Wang and Zubieta) and Department of Radiology (Drs Koeppe and Zubieta), University of Michigan, Ann Arbor; and School of Dentistry, University of Maryland, Baltimore (Dr Stohler).